Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Certain anaerobic microbes with the capability to colonize the tumor microenvironment tend to express the heterologous gene in a sustainable manner, which will inevitably compromise the therapeutic efficacy and induce off-tumor toxicity in vivo. To improve the therapeutic precision and controllability of bacteria-based therapeutics, Escherichia coli Nissle 1917 (EcN), engineered to sense blue light and release the encoded flagellin B (flaB), is conjugated with lanthanide upconversion nanoparticles (UCNPs) for near-infrared (NIR) nano-optogenetic cancer immunotherapy. Upon 808 nm photoirradiation, UCNPs emit at the blue region to photoactivate the EcN for secretion of flaB, which subsequently binds to Toll-like receptor 5 expressed on the membrane of macrophages for activating immune response via MyD88-dependent signal pathway. Such synergism leads to significant tumor regression in different tumor models and metastatic tumors with negligible side effects. These studies based on the NIR nano-optogenetic platform highlight the rational of leveraging the optogenetic tools combined with natural propensity of certain bacteria for cancer immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/adma.202207198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dual-Mode Hybrid Discharge Plasma-Activated Injectable Hydrosol for Enhanced Immunotherapeutic Cancer Therapy.
Adv Healthc Mater
September 2025
Department of Physics, Department of Materials Science and Engineering, and Department of Biomedical Engineering, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong, China.
Although cold atmospheric plasma is a promising therapeutic technique for tumor immunotherapy via reactive oxygen and nitrogen species (RONS), the challenges associated with the generation and delivery of these RONS hamper clinical adoption. Herein, a dual-mode hybrid discharge plasma-activated sodium alginate hydrosols (PAH) is proposed to enhance the antitumor immune response. Gaseous highly reactive RONS are generated by dual-mode hybrid plasma produced by mixed O and NO modes, which are converted into aqueous RONS in PAH via gas-liquid reactions between plasma and hydrosols.
View Article and Find Full Text PDFPrognostic role of the baseline neutrophil‒eosinophil ratio in cancer patients: a meta-analysis and systematic review.
World J Surg Oncol
September 2025
Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background: Inflammation impacts the prognosis of numerous types of tumors. Inflammatory indicators such as the neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and neutrophil-to-eosinophil ratio (NER) have emerged as potential prognostic markers and are closely correlated with the outcomes of cancer patients. However, the connection between NER and cancer prognosis remains incompletely understood.
View Article and Find Full Text PDFHarnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology.
Clin Transl Oncol
September 2025
Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman, University, P.O.Box 84428, 11671, Riyadh, Saudi Arabia.
Esophageal cancer (EC) is one of the most serious health issues around the world, ranking seventh among the most lethal types of cancer and eleventh among the most common types of cancer worldwide. Traditional therapies-such as surgery, chemotherapy, and radiation therapy-often yield limited success, especially in the advanced stages of EC, prompting the pursuit of novel and more effective treatment strategies. Immunotherapy has emerged as a promising option; nonetheless, its clinical success is hindered by variable patient responses.
View Article and Find Full Text PDFImmunotherapy in advanced hepatocellular cancer: The last piece of the puzzle.
J Hepatol
September 2025
Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, Hammersmith Hospital, Du Cane Road, W120NN, London, UK; Department of Translational Medicine (DIMET), University of Piemonte Orientale "A. Avogadro", Novara, Italy.
Response to "Neoadjuvant or Perioperative Chemoimmunotherapy Treatment in Patients With Resectable NSCLC: Still an Open Question" by Dafni et al.
J Thorac Oncol
September 2025
Thoracic Surgery Unit, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy; Tumor Immunology and Immunotherapy Unit, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. Electronic address: